Literature DB >> 31659640

PRAME as a Potential Biomarker for Liver Metastasis of Gastric Cancer.

Hayato Baba1,2, Mitsuro Kanda3, Koichi Sawaki2, Shinichi Umeda2, Takashi Miwa2, Dai Shimizu2, Chie Tanaka2, Daisuke Kobayashi2, Michitaka Fujiwara2, Yasuhiro Kodera2, Tsutomu Fujii1.   

Abstract

BACKGROUND: Liver metastasis of gastric cancer (GC) is highly associated with poor prognosis. The development of sensitive biomarkers for detecting and predicting liver metastasis is required for better clinical outcome.
OBJECTIVE: In this study, we aimed to identify novel genes associated with liver metastasis of GC.
METHODS: Global expression profiling of 57,749 genes was performed using surgically resected gastric tissues from four patients with liver metastasis to identify candidate genes. The mRNA expression levels of the selected candidate gene were analyzed in the resected gastric tissues of 300 GC patients and correlated with clinicopathological parameters. Fourteen GC cell lines were subjected to mRNA expression and polymerase chain reaction (PCR) array analysis.
RESULTS: Among 25 candidate genes identified by transcriptome analysis, preferentially expressed antigen of melanoma (PRAME) was selected for subsequent analyses. mRNA expression analysis of clinical samples revealed the aberrant expression of PRAME in GC tissues, and its high expression was significantly related to differentiated phenotype and vessel invasion, as well as liver metastasis. High PRAME expression was significantly associated with hepatic recurrence after curative surgery, and cumulative incidences of hepatic recurrence were significantly greater in patients with high PRAME expression compared with patients with low PRAME expression. In an in vitro analysis, overexpression was observed in all GC cell lines compared with a normal epithelial cell line. PCR array analysis revealed the coordinate expression of MMP9, OCLN, IL1RN, and MST1R.
CONCLUSIONS: PRAME is related to the malignant potential of GC and could serve as a novel biomarker for the detection and prediction of liver metastasis.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31659640     DOI: 10.1245/s10434-019-07985-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  2 in total

1.  The prognosis role of AJCC/UICC 8th edition staging system in gastric cancer, a retrospective analysis.

Authors:  Jiu-Yang Liu; Chun-Wei Peng; Xiao-Jun Yang; Chao-Qun Huang; Yan Li
Journal:  Am J Transl Res       Date:  2018-01-15       Impact factor: 4.060

2.  Integrated multigene expression panel to prognosticate patients with gastric cancer.

Authors:  Mitsuro Kanda; Kenta Murotani; Haruyoshi Tanaka; Takashi Miwa; Shinichi Umeda; Chie Tanaka; Daisuke Kobayashi; Masamichi Hayashi; Norifumi Hattori; Masaya Suenaga; Suguru Yamada; Goro Nakayama; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Oncotarget       Date:  2018-04-10
  2 in total
  4 in total

1.  Gamma-aminobutyric Acid Type A Receptor Subunit Delta as a Potential Therapeutic Target in Gastric Cancer.

Authors:  Koichi Sawaki; Mitsuro Kanda; Hayato Baba; Yoshikuni Inokawa; Norifumi Hattori; Masamichi Hayashi; Chie Tanaka; Yasuhiro Kodera
Journal:  Ann Surg Oncol       Date:  2022-09-20       Impact factor: 4.339

2.  Machine learning algorithm of ultrasound-mediated intestinal function recovery and nursing efficacy analysis of lower gastrointestinal malignant tumor after surgery.

Authors:  Lei Ma; Hao Zhang
Journal:  Pak J Med Sci       Date:  2021       Impact factor: 1.088

3.  PRAME protein expression in DICER1-related tumours.

Authors:  Paul S Thorner; Anne-Sophie Chong; Javad Nadaf; Naciba Benlimame; Paula Marrano; Rose Chami; Lili Fu; William D Foulkes
Journal:  J Pathol Clin Res       Date:  2022-03-16

4.  RNA expression profiling reveals PRAME, a potential immunotherapy target, is frequently expressed in solitary fibrous tumors.

Authors:  Wei-Lien Wang; Nalan Gokgoz; Bana Samman; Irene L Andrulis; Jay S Wunder; Elizabeth G Demicco
Journal:  Mod Pathol       Date:  2020-10-02       Impact factor: 7.842

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.